Tomov S, Popovska S, Veselinova T, Gorchev G, Velkova A
Akush Ginekol (Sofiia). 2005;44 Suppl 2:42-7.
To study the frequency of EGFR expression in patients having malignant and benign ovarian tumors and to analyze its relation to some clinico-pathological factors.
In a prospective study 71 patients with malignant and 19 with benign ovarian tumors were included for the period 1999-2004. We utilized immunohistochemical analysis with monoclonal mouse antihuman EGFR antibody and EGFR pharm Dx kit (DAKO).
The frequency of EGFR expression for the malignant ovarian tumours was 62.9% compared to 36.8% for the benign ones (p = 0.042). The patients with peritoneal washing positive for tumour cells and those with progressing cancer express EGFR significantly more frequently, 77% and 75%, respectively (p = 0.05).
Malignant ovarian tumours have significantly greater frequency of EGFR expression compared to benign ovarian tumours.
研究恶性和良性卵巢肿瘤患者表皮生长因子受体（EGFR）的表达频率，并分析其与某些临床病理因素的关系。
在一项前瞻性研究中，纳入了1999年至2004年期间71例恶性卵巢肿瘤患者和19例良性卵巢肿瘤患者。我们使用单克隆小鼠抗人EGFR抗体和EGFR药物诊断试剂盒（达科公司）进行免疫组织化学分析。
恶性卵巢肿瘤的EGFR表达频率为62.9%，而良性卵巢肿瘤为36.8%（p = 0.042）。腹水肿瘤细胞阳性患者和癌症进展患者EGFR表达频率明显更高，分别为77%和75%（p = 0.05）。
与良性卵巢肿瘤相比，恶性卵巢肿瘤的EGFR表达频率明显更高。
